{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:09:48Z","timestamp":1785920988205,"version":"3.56.0"},"reference-count":98,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>\n                    Targeted \u03b1 therapy (TAT) offers the potential for the targeted delivery of potent \u03b1-particle-emitting radionuclides that emit high linear energy transfer radiation. This leads to a densely ionizing radiation track over a short path. Localized radiation induces cytotoxic, difficult-to-repair, clustered DNA double-strand breaks (DSBs). To date, radium-223 (\n                    <jats:sup>223<\/jats:sup>\n                    Ra) is the only TAT approved for the treatment of patients with metastatic castration-resistant prostate cancer. Thorium-227 (\n                    <jats:sup>227<\/jats:sup>\n                    Th), the progenitor nuclide of\n                    <jats:sup>223<\/jats:sup>\n                    Ra, offers promise as a wider-ranging alternative due to the availability of efficient chelators, such as octadentate 3,2-hydroxypyridinone (3,2-HOPO). The 3,2-HOPO chelator can be readily conjugated to a range of targeting moieties, enabling the generation of new targeted thorium-227 conjugates (TTCs). This review provides a comprehensive overview of the advances in the preclinical development of TTCs for hematological cancers, including CD22-positive B cell cancers and CD33-positive leukemia, as well as for solid tumors overexpressing renal cell cancer antigen CD70, membrane-anchored glycoprotein mesothelin in mesothelioma, prostate-specific membrane antigen in prostate cancer, and fibroblast growth factor receptor 2. As the mechanism of action for TTCs is linked to the formation of DSBs, the authors also report data supporting combinations of TTCs with inhibitors of the DNA damage response pathways, including those of the ataxia telangiectasia and Rad3-related protein, and poly-ADP ribose polymerase. Finally, emerging evidence suggests that TTCs induce immunogenic cell death through the release of danger-associated molecular patterns. Based on encouraging preclinical data, clinical studies have been initiated to investigate the safety and tolerability of TTCs in patients with various cancers.\n                  <\/jats:p>","DOI":"10.1089\/cbr.2020.3568","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T17:54:03Z","timestamp":1586282043000},"page":"497-510","source":"Crossref","is-referenced-by-count":24,"title":["Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy"],"prefix":"10.1177","volume":"35","author":[{"given":"Urs B.","family":"Hagemann","sequence":"first","affiliation":[{"name":"Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Wickstroem","sequence":"additional","affiliation":[{"name":"Bayer AS, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hammer","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Bjerke","sequence":"additional","affiliation":[{"name":"Bayer AS, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Zitzmann-Kolbe","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav B.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Bayer AS, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Bayer AS, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Scholz","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Hennekes","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Mumberg","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Cuthbertson","sequence":"additional","affiliation":[{"name":"Bayer AS, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570163812666150602144310"},{"key":"e_1_3_5_3_2","unstructured":"Mukherjee S. The Emperor of All Maladies: A Biography of Cancer. New York: Scribner 2010."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2016.1185412"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2955"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.190124"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.116.175034"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4044"},{"key":"e_1_3_5_10_2","unstructured":"Xofigo (Radium Ra 223 Dichloride) Injection\u2014Access Data FDA. Online document at www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203971lbl.pdf Accessed on November18 2019."},{"key":"e_1_3_5_11_2","unstructured":"European Medicines Agency. Xofigo. Online document at https:\/\/ema.europa.eu\/medicines\/human\/EPAR\/xofigo Accessed on November18 2019."},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0251-x"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70183-4"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw065"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv380"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8043(01)00282-2"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.3934\/medsci.2015.3.228"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2005.20.557"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2300"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0256"},{"key":"e_1_3_5_22_2","first-page":"1881","article-title":"Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice","volume":"40","author":"Tan Z","year":"2012","unstructured":"Tan Z, , Chen P, , Schneider N, et al. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Int J Oncol, 2012; 40:1881.","journal-title":"Int J Oncol"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2013.1531"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.143842"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000353"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.07.034"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0859"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234559"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tby010"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.4.3.459"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph8020321"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1524\/ract.2013.2047"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.inorgchem.8b02430"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2005.12.004"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042345"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2010.12.010"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3476"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.104"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2427-6"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.06.021"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(05)88001-0"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50057"},{"key":"e_1_3_5_43_2","first-page":"241","article-title":"CD22 as a target for cancer therapy","volume":"9","author":"Tu X","year":"2011","unstructured":"Tu X, , LaVallee T, , Lechleider R. CD22 as a target for cancer therapy. J Exp Ther Oncol, 2011; 9:241.","journal-title":"J Exp Ther Oncol"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S34273"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25410"},{"key":"e_1_3_5_46_2","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties","volume":"9","author":"Carnahan J","year":"2003","unstructured":"Carnahan J, , Wang P, , Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin Cancer Res, 2003; 9:3982S.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0294"},{"key":"e_1_3_5_48_2","unstructured":"Lumoxiti (Moxetumomab Pasudotox\u2013tdfk) for the Treatment of Hairy Cell Leukaemia. Online document at https:\/\/clinicaltrialsarena.com\/projects\/moxetumomab-pasudotox-hairy-cell-leukaemia\/ Accessed on February12 2020."},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0210-1"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-440X(02)00375-5"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0251"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-019-0169-8"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0337"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0801"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0583"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S145105"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-591"},{"issue":"10","key":"e_1_3_5_59_2","first-page":"S13","article-title":"Overview of prostate-specific membrane antigen","volume":"6","author":"Chang SS.","year":"2004","unstructured":"Chang SS. Overview of prostate-specific membrane antigen. Rev Urol, 2004; 6(suppl10):S13.","journal-title":"Rev Urol"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23642"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30534-5"},{"key":"e_1_3_5_62_2","unstructured":"ClinicalTrials.gov. NCT03511664. Online document at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03511664 Accessed on December18 2019."},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4167-0"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0552"},{"key":"e_1_3_5_66_2","doi-asserted-by":"crossref","unstructured":"Hammer S Hagemann UB Zitzmann-Kolbe S et al. Preclinical efficacy of a prostate specific membrane antigen-targeted thorium-227 conjugate (PSMA-TTC) a targeted alpha therapy for prostate cancer. Clin Cancer Res 2019; [Epub ahead of print]; DOI: 10.1158\/1078-0432.CCR-19-2268.","DOI":"10.1158\/1078-0432.CCR-19-2268"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.07.007"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01573.x"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.05.005"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000158121.49085.ba"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2016.1158812"},{"key":"e_1_3_5_72_2","first-page":"2592","article-title":"Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma","volume":"62","author":"Wischhusen J","year":"2002","unstructured":"Wischhusen J, , Jung G, , Radovanovic I, et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res, 2002; 62:2592.","journal-title":"Cancer Res"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16910"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2780"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2014.11.003"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.489"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3746"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-5199"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm500389b"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5b00572"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-1141"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-5200"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-844"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph12040155"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.2508"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223701"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00335-018-9777-0"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.954925"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2014.04.002"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13520"},{"key":"e_1_3_5_94_2","unstructured":"ClinicalTrials.gov. NCT02581878. Online document at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02581878 Accessed on November8 2019."},{"key":"e_1_3_5_95_2","unstructured":"ClinicalTrials.gov. NCT03507452. Online document at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03507452 Accessed on November14 2019."},{"key":"e_1_3_5_96_2","unstructured":"ClinicalTrials.gov. NCT03724747. Online document at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03724747 Accessed on November14 2019."},{"key":"e_1_3_5_97_2","unstructured":"ClinicalTrials.gov. NCT04147819. Online document at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04147819 Accessed on January2 2020."},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5203-y"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0382-x"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2020.3568","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2020.3568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2020.3568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:15:34Z","timestamp":1777385734000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2020.3568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":98,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1089\/cbr.2020.3568"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2020.3568","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]}}}